OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

Published

November 12, 2018

OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

A new UK biotech, OMass Therapeutics, has been spun out of the chemistry department at the University of Oxford to exploit expertise in “native” mass spectrometry, a technology investors believe has potential in helping to build a portfolio of novel drugs…

MORERelated News
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...
No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work
OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five...